



Murphy, E. and Shelley, B. (2019) Clinical presentation and management of right ventricular dysfunction. *BJA Education*, 19(6), pp. 183-190. (doi: [10.1016/j.bjae.2019.02.004](https://doi.org/10.1016/j.bjae.2019.02.004))

The material cannot be used for any other purpose without further permission of the publisher and is for private use only.

There may be differences between this version and the published version. You are advised to consult the publisher's version if you wish to cite from it.

<http://eprints.gla.ac.uk/181578/>

Deposited on 11 March 2019

Enlighten – Research publications by members of the University of
Glasgow

<http://eprints.gla.ac.uk>



Clinical Aspects of the Right Ventricle in Anaesthesia and Intensive Care

Journal:	<i>BJA Education</i>
Manuscript ID	BJAED-2018-044.R2
Article Type:	Invited Review
Date Submitted by the Author:	17-Feb-2019
Complete List of Authors:	Shelley, Ben; Golden Jubilee National Hospital, Anaesthesia and Critical Care; University of Glasgow School of Life Sciences, Academic Unit of Anaesthesia Murphy, Emma; Golden Jubilee National Hospital, Department of Anaesthesia
Mesh keywords	right ventricle, Right ventricular dysfunction, critical care.

SCHOLARONE™
Manuscripts

Clinical Presentation and Management of Right Ventricular Dysfunction

Emma Murphy MBCHB, MRCP

Clinical Research Fellow in Cardiothoracic Anaesthesia and Intensive Care

Department of Anaesthesia, Golden Jubilee National Hospital, Glasgow, UK

Academic Unit of Anaesthesia, Critical Care and Pain Medicine, Glasgow, University.

Benjamin Shelley MBCHB, FRCA, FFICM, MD

Consultant in Cardiothoracic Anaesthesia and Intensive Care

Department of Anaesthesia, Golden Jubilee National Hospital, Glasgow, UK

Academic Unit of Anaesthesia, Critical Care and Pain Medicine, Glasgow, University.

Corresponding author:

Dr Benjamin Shelley

Department of Anaesthesia

Golden Jubilee National Hospital

Agamemnon Street

Clydebank

Glasgow

UK

G81 4DY

Email: Benjamin.Shelley@glasgow.ac.uk

1
2
3 Telephone: 0141 951 5000
4
5
6
7

8 Keywords: Right ventricle, Right ventricular dysfunction, anaesthesia, general, and critical
9
10 care.
11
12
13
14

15 Key Points:
16
17
18
19

- 20 1. Right ventricular (RV) dysfunction may be encountered in a wide variety of clinical
21 scenarios
22
- 23 2. Identifying the underlying aetiology is important to optimising the RV.
24
- 25 3. Key management principles involve optimising rate, rhythm, perfusion, and preload,
26 whilst maintaining contractility and minimising afterload.
27
- 28 4. 'Traditional' mechanical ventilation strategies may worsen RV dysfunction.
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Learning Objectives:
4

5
6 By reading this article you should be to:
7

- 8 • Describe a variety of conditions where right ventricular (RV) dysfunction might occur
- 9
- 10 • Describe a strategy for management of RV dysfunction including an approach to
- 11 rate, rhythm, perfusion, preload, contractility, and afterload.
- 12
- 13 • Be aware of the complex interaction between mechanical ventilation and RV
- 14 dysfunction.
- 15
- 16 • Have a basic understanding of the mechanical support options available when
- 17 pharmacological management fails.
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

Introduction

The importance of identifying and managing right ventricular (RV) dysfunction is becoming increasingly recognised by both anaesthetist and intensivist. In the face of an ageing population, with a broad range of increasingly complex comorbidities, the importance of RV function is applicable to a far wider population than those undergoing cardiothoracic surgery. Early recognition of RV dysfunction is essential to prevent failure and improve morbidity and mortality. An approach to RV structure and function was discussed in part one of this series with the aim of this second article to provide an overview of the clinical conditions leading to RV dysfunction and outline an approach to managing these patients.¹

Right ventricular failure (RVF) is a heterogeneous syndrome, with a wide variety of aetiologies (both acute and chronic) requiring individualised treatment.² Whilst RVF lacks a validated consensus definition, the term acute right heart syndrome (ARHS) has recently been described, and is defined as a rapidly progressive syndrome with systemic congestion resulting from impaired RV filling and or reduced RV flow output.²

A high index of suspicion is required in patients with potential acute RV dysfunction as signs and symptoms may be non-specific. Acute signs of RVF are mainly a result of low cardiac output (CO) or systemic venous congestion and include signs of hypoperfusion with deranged liver function tests, elevated urea and creatinine, high lactate, and low venous oxygen saturations, all of which are non-specific to the diagnosis of RV failure. Signs and symptoms of chronic RV failure, such as ascites, exertional dyspnoea, reduced exercise tolerance, and ankle swelling may not always be present. Early use of transthoracic

1
2
3 echocardiography (TTE) is recommended in those with a suspicion of RV failure to aid the
4
5 early diagnosis in a challenging cohort of patients with limited specific clinical signs.³
6
7
8
9

10 **Clinical Conditions in which RV failure may be encountered**

11
12
13
14

15 RV function can be impaired by either volume or pressure overload states or a reduction in
16
17 myocardial contractility. Dysfunction is triggered by an injury or stress to the RV with
18
19 adaptation dependant on the nature of the insult, the duration of the disease, and time of
20
21 onset (i.e. birth, childhood or adulthood). **Acute events, as seen in myocardial infarction**
22
23 **(MI) or pulmonary embolism (PE), may quickly progress to RV failure due to impaired**
24
25 **contractility or acutely increased afterload. In chronic diseases, such as pulmonary**
26
27 **hypertension (PH) or congenital cardiac disease, a gradual increase in RV afterload allows**
28
29 **adaptive mechanisms to develop which preserve CO over a longer period of time before**
30
31 **decompensation occurs.**
32
33
34
35
36
37
38

39 Generally, the RV adapts better to volume overload, as seen with tricuspid regurgitation
40
41 (TR) and atrial septal defects (ASDs), and can withstand these conditions for a long period of
42
43 time without significant change in RV systolic function. **Acute pressure overload, as seen in**
44
45 **PE, leads to a rapid rise in pulmonary vascular resistance (PVR), increased afterload and RV**
46
47 **wall tension, which quickly leads to RV dilatation and failure. Chronic pressure overload,**
48
49 **commonly seen in PH, results in the RV being able to adapt as the pressure increases**
50
51 **gradually over time. Multiple compensatory measures exist in chronic pressure overload**
52
53 **including myocyte hypertrophy, expansion of the extracellular matrix, reduction in wall**
54
55 **stress, and upregulation of neurohormonal systems. Over time, the gradual increase in**
56
57
58
59
60

1
2
3 afterload results in a decrease in contractility, leading to progressive RV dilation and
4
5 ultimately failure.
6
7
8
9

10 When considering the aetiology of RV dysfunction, it can be useful to categorise into those
11 affecting preload, afterload and contractility. Increased preload may occur in TR and ASDs.
12
13 Increased afterload may occur due PH and PE. Decreased contractility may be encountered
14
15 in RV infarction, arrhythmias or sepsis. In critically ill patients, RV dysfunction can often be
16
17 multifactorial e.g. with sepsis induced acute respiratory distress syndrome (ARDS) where RV
18
19 function may be impaired by both increased afterload and reduced contractility.
20
21
22
23
24
25
26
27

- 28 • *Pulmonary Hypertension*

29
30
31
32
33 PH is defined by a mean pulmonary artery pressure ≥ 25 mm Hg at rest, and is the
34
35 commonest cause of RV failure.⁴ The World Health Organisation classifies PH into 5 broad
36
37 classifications: 1) pulmonary arterial hypertension, 2) PH secondary to left heart disease, 3)
38
39 PH associated with lung disease, 4) chronic thromboembolic PH and 5) miscellaneous
40
41 including haematological, metabolic and systemic disorders.⁴ Classifications 1,3, and 4 are
42
43 ‘precapillary’ and demonstrate a low or normal pulmonary capillary wedge pressure (a
44
45 surrogate measure of left atrial pressure).
46
47
48
49
50
51

52 In PH, remodelling of the pulmonary vasculature, hypoxic vasoconstriction and disruption
53
54 and fibrosis of small pulmonary vessels result in a steady increase in PVR. Increased
55
56 afterload and disruption of neuroendocrine and autocrine signals leads to cardiomyocyte
57
58 loss, myocardial ischaemia and remodelling. Initially, this increased afterload can be
59
60

1
2
3 compensated for by RV hypertrophy, but eventually, the RV can no longer compensate and
4 dilatation and dysfunction occur. The RV's ability to adapt to pressure overload determines
5 prognosis in PH with a dilated RV shown to predict poor survival.⁵
6
7
8
9

10
11
12
13 Managing patients with PH in a critical care setting can be challenging and complex;
14
15 pulmonary vasodilators, less commonly used in a general ICU environment, may be required
16
17 with consideration given to early advice from a PH centre.⁶ Condliffe et al have recently
18
19 published 'Critical Care Management of Pulmonary Hypertension' which provides an in-
20
21 depth review of PH in the ICU setting.⁶
22
23
24
25

26
27
28 Special attention should be given to patients with preexisting PH undergoing surgery as they
29
30 are at high risk of deterioration. The chosen anaesthetic technique should aim to prevent
31
32 further iatrogenic increases in PAP by preventing hypoxia, hypercapnia, and acidosis. The
33
34 use of PEEP, intraoperative patient positioning, and pneumoperitoneum can all increase
35
36 afterload. Intraoperative invasive monitoring is likely to be required and the use of
37
38 transoesophageal echocardiography (TOE) and CO monitoring devices may be appropriate.
39
40
41
42 Neuraxial techniques can be used; however, consideration should be given to the risk of
43
44 cardiovascular instability with sympathetic block. These patients are likely to require critical
45
46 care following surgery with high-risk of post-operative RV failure. Depending on the nature
47
48 and urgency of the surgery, referral to a PH centre for advice may be appropriate.
49
50
51
52
53
54
55
56

- 57 • *Left Ventricular (LV) Failure*
58
59
60

1
2
3 The commonest cause of PH is left-sided heart failure which includes LV systolic dysfunction,
4
5 LV diastolic dysfunction and left-sided valvular heart disease.⁴ LV failure is classified as post
6
7 capillary PH (class II) and is associated with a high pulmonary capillary wedge pressure.⁴ In
8
9 this instance, PH develops occurs as a result of passive backward transmission of raised left
10
11 sided filling pressures. Associated RV dysfunction often goes unrecognised despite a
12
13 prevalence of around one fifth of patients with LV failure.⁷ RV failure is an important
14
15 independent predictor of survival in patients with LV failure.⁷ As with all cases of RV failure,
16
17 monitoring of both the LV and RV with echocardiography is essential. In patients with RV
18
19 failure as a result of raised left sided filling pressures, benefit may be derived from left heart
20
21 failure management strategies including revascularisation, diuresis, and the use of beta
22
23 blockers and angiotensin converting enzyme inhibitors. In some preoperative patients, it
24
25 may be beneficial to delay surgery in order to optimise heart failure management prior to
26
27 surgery.
28
29
30
31
32
33
34
35
36
37
38
39

- 40 • *Chronic Obstructive Pulmonary Disease (COPD)*

41
42
43 COPD is the most common cause of cor pulmonale and leads to an increase in RV afterload
44
45 secondary to changes in pulmonary vascular structure and mechanics, and lung
46
47 hyperinflation. Patients with COPD who subsequently develop RV dysfunction have an
48
49 increased risk of admission to hospital and mortality.⁸
50
51
52
53
54

55 It is often not appreciated that these changes are not just limited to those with severe lung
56
57 disease; studies demonstrate remodelling of the pulmonary vasculature occurs in those with
58
59
60

1
2
3 mild disease and in smokers with normal lung function.⁹ As such, there is good evidence to
4
5 show that patients with mild to moderate COPD (well within the realms of lung function
6
7 seen in patients presenting for a wide range of elective surgeries) have exercise limitation
8
9 resulting from cardiac (i.e. RV) rather than respiratory insufficiency. Arguably, the COPD
10
11 population should be considered 'at risk' of RV dysfunction during the perioperative period
12
13 and may be less tolerant of the stresses of mechanical ventilation and critical illness. The
14
15 development of disproportionate haemodynamic collapse following intubation in the COPD
16
17 patient with 'single organ' postoperative respiratory failure is a classic example of this.
18
19
20
21
22
23
24
25
26
27

- 28 • *Pulmonary Embolism (PE)*

29
30
31
32
33 PE is the commonest cause of acute RV dysfunction; assessment of RV function is essential
34
35 as mortality is directly related to the extent of RV failure.¹⁰ Mechanical obstruction of
36
37 pulmonary vessels results in acutely increased RV afterload. Acute dilatation and stretch of
38
39 the RV muscle occurs when more than 30% of the pulmonary vasculature is blocked,
40
41 increasing RV wall tension with an increasing oxygen demand whilst simultaneously
42
43 decreasing perfusion.¹¹ In most cases of PE, as resolution of the embolus occurs over time,
44
45 pulmonary artery pressures (PAP) decline and RV function returns to normal.
46
47
48
49
50

51
52
53 Chronic thromboembolic PH (CTEPH) is a rare complication of PE and occurs as a result of
54
55 incomplete resolution of the clot with the formation of a fibrotic and flow limiting thrombus
56
57 within the pulmonary vasculature. These changes lead to an increase in afterload with
58
59
60

1
2
3 remodelling of both the pulmonary vasculature and the RV. Pulmonary endarterectomy may
4
5 be appropriate for some patients; however, RV dysfunction may persist following surgery as
6
7 a result of the extent of RV remodelling which has taken place.¹²
8
9

10
11
12
13 • *Acute Respiratory Distress Syndrome*
14

15
16 Acute cor pulmonalae has been reported in 20-25% of patients with ARDS with good
17
18 evidence to suggest that RV dysfunction is independently associated with poor outcome.¹³ A
19
20 high index of suspicion is therefore required for the potential diagnosis of PH and RV
21
22 dysfunction in those with ARDS as the clinical signs are often non-specific.
23
24
25

26
27
28
29
30 ARDS causes direct injury to the pulmonary circulation caused by hypoxic vasoconstriction,
31
32 extrinsic vascular compression as a result of interstitial oedema, vasoconstrictor mediator
33
34 release, and blood vessel remodelling. Endothelial dysfunction is a common feature
35
36 alongside mechanical obstruction as a consequence of thromboemboli particularly in the
37
38 larger pulmonary arteries, veins, and lymphatics whilst smaller vessels become occluded by
39
40 neutrophils and platelets.¹⁴ This leads to an increase in PVR, RV afterload, the development
41
42 of PH and RV failure. In patients with ARDS, these effects are magnified as airway pressures
43
44 rise in combination with the pulmonary vasoconstrictive effects of hypoxia and hypercapnia.
45
46
47
48
49
50

51
52
53
54 It is increasingly being recognised that modern ventilatory practices with low tidal volumes
55
56 and high PEEP have the potential to adversely affect RV function, with some experts
57
58 recommending an 'RV protective approach' to mechanical ventilation in ARDS, such that
59
60

1
2
3 PEEP is manipulated in parallel with echocardiographic assessment of the RV. Such an RV
4
5 protective strategy focuses on limiting plateau pressure to reduce lung stress, improving
6
7 oxygenation to limit the effect of hypoxic vasoconstriction and preventing hypercapnia.¹⁵
8
9
10 Tidal volume and PEEP should aim to maintain a plateau pressure <27cmH₂O, a driving
11
12 pressure <18cmH₂O and ideally a PaCO₂ <48mmHg.¹⁵ If the respiratory rate is adjusted, this
13
14 should be done carefully as this may induce intrinsic PEEP and dynamic hyperinflation
15
16 worsening RV dysfunction. Ventilation in the prone position has been shown to induce
17
18 alveolar recruitment and reduce RV afterload.¹⁶
19
20
21
22
23
24
25
26

- 27 • *Obesity and Obstructive Sleep Apnoea*

28
29
30
31
32 Obesity is an independent risk factor for cardiovascular disease and has been shown to
33
34 cause a wide spectrum of cardiovascular changes which can ultimately result in heart
35
36 failure. Obesity can lead to RV dysfunction as a result of increased CO, obesity
37
38 hypoventilation syndrome and obstructive sleep apnoea (OSA). Studies have shown the
39
40 presence of RV dilatation, increased RV wall thickness and subclinical RV diastolic and
41
42 systolic impairment may be present in young obese patients with no pre-existing
43
44 cardiovascular disease.¹⁷
45
46
47
48
49
50

51
52 In OSA, hypoxic pulmonary vasoconstriction occurs during apnoeic episodes leading to
53
54 remodelling of the pulmonary microcirculation increasing PVR, and ultimately leading to the
55
56 development of PH and subsequent RV dysfunction.¹⁸ Negative intrathoracic pressure,
57
58 occurring during inspiration against an occluded pharynx, increases venous return, and RV
59
60

1
2
3 preload.¹⁸ Co-existing cardiovascular disease and hypoxaemia may also play an important
4
5 role in RV dysfunction in this patient population. Imaging of the RV by TTE can be
6
7 challenging in this cohort of patients and consideration may be given to more advanced
8
9 techniques.
10
11
12
13
14

15 Careful attention to mechanical ventilation strategies is also required to prevent atelectasis
16
17 but prevent further RV dysfunction (necessitating a similarly balanced ventilation strategy as
18
19 described in ARDS).
20
21
22
23
24

- 25 • *Right ventricle myocardial infarction (RVMI)*
26
27
28
29
30

31 As the RV is supplied by the right coronary artery (RCA) in 80% of the population, RCA
32
33 occlusion can lead to significant RV ischaemia. Generally, the RV is considered to more
34
35 tolerant of an ischemic insult compared with the LV as a result of coronary perfusion
36
37 occurring throughout the cardiac cycle, and reduced myocardial oxygen demand¹⁹. Patients
38
39 with a proximal RCA MI, however, have an increased risk of tachyarrhythmia, cardiogenic
40
41 shock and death because of the interruption of the blood flow to the AV node and the lack
42
43 of collateral blood supply present in the RV. Prognosis in RVMI is dependent on the location
44
45 of the MI, presence of complications, preexisting RV dysfunction, and successful coronary
46
47 reperfusion. Similar to LVMI, patients who survive RVMI, may recover their systolic function
48
49 following the initial ischaemic episode as 'stunning' resolves.
50
51
52
53
54
55
56
57

- 58 • *Congenital Heart Disease*
59
60

1
2
3 Several different types of congenital heart disease are associated with RV dysfunction. Both
4 atrial and ventricular septal defects (A- and V-SD) with left to right shunt and tricuspid and
5 pulmonary regurgitation may lead to volume overloaded RV failure. Chronically increased
6 pulmonary blood flow can occur in large septal defects leading to pulmonary endothelial
7 damage, thrombosis, RV hypertrophy and pulmonary vascular remodelling. If unchecked,
8 progressive hypertrophy and increasing right sided systolic pressure result in
9
10 'suprasystemic' right sided pressures and reversal of the initially left-to-right shunt. This
11 results in right-to-left shunting and consequent systemic hypoxemia as seen in
12 Eisenmenger's syndrome.^{19 20}

13
14
15
16
17
18
19
20
21
22
23
24
25
26
27 Pressure-overloaded RV failure occurs with pulmonary stenosis, RV outflow tract (RVOT)
28 obstruction after correction of tetralogy of Fallot (TOF), and repair of transposition of the
29 great arteries. Whilst the RV is initially able to adapt, (if untreated) longstanding obstruction
30 leads to progressive TR and RV dilation and failure.²⁰ Over time pulmonary regurgitation
31 leads to progressive RV dilatation necessitating timely PV replacement before RV
32 dysfunction ensues.²⁰ Adult patients with TOF repaired in childhood are becoming an
33 increasingly large cohort in congenital cardiac centres.

- 44
45
46
47 • *Cardiac Surgery*

48
49
50 A degree of RV dysfunction following cardiac surgery is commonplace; however, the
51 underlying aetiology is not clear. Besides the effects of myocardial stunning resulting from
52 direct myocardial ischaemia during cardiopulmonary bypass, the RV is particularly
53 susceptible to post-operative dysfunction because of air embolization (to which the RV is
54
55
56
57
58
59
60

1
2
3 particularly predisposed as a result of the anterior location of the right coronary ostia), and
4
5 increased PVR postoperatively. Where systemic vasodilatation is common following
6
7 cardiopulmonary bypass, PVR commonly rises as a result of the activation of inflammatory
8
9 mediators, the accumulation of extravascular lung water, persistent pulmonary de-
10
11 recruitment and protamine-induced PH.
12
13
14
15
16
17

18 PH, RV dilatation and dysfunction, and functional TR are common sequelae of mitral valve
19
20 disease. At the time of mitral valve surgery, the tricuspid valve (TV) may also be repaired.
21
22 Careful attention to the RV following TV surgery is paramount. Pre-operatively TR can lead
23
24 to overestimation of baseline RV function as it is 'flattered' by the presence of TR (i.e. the
25
26 ease of emptying when blood may flow in an anterograde or retrograde direction can make
27
28 the function 'look' better than it is). Repair of the valve can then lead to an effective
29
30 increase in afterload which may unmask impaired RV function.
31
32
33
34
35
36

- 37 • *Left Ventricular Assisted Devices (LVAD)*

38
39
40 LVADs are used as a bridge to transplant or recovery in patients with severe heart failure. An
41
42 inlet cannula is inserted into the LA or LV cavity, whilst an outflow graft is attached to the
43
44 ascending aorta providing isolated support to the left-side of the heart. Adequacy of RV
45
46 function is a major determinant of outcome following LVAD insertion. In comparison to the
47
48 low cardiac output state encountered pre-operatively, following LVAD implantation, the RV
49
50 is challenged by the need to match the increased LV output which leads to an effective
51
52 increase in preload. In addition, unloading of the LV by a VAD can alter the shape and size of
53
54 the RV leading to a direct effect on function.²¹
55
56
57
58
59
60

- *Heart Transplantation*

Despite advances in the perioperative management of heart transplantation, acute RV failure still accounts for a significant number of complications and early deaths. Whilst the aetiology for RV failure following transplantation is multifactorial, two predominant mechanisms are described. Firstly, that of an ischaemic insult to the RV occurring as a result of prolonged ischaemic time and sub-optimal myocardial protection leading directly to primary graft failure. Secondly, the presence of pre-existing or acquired PH in the recipient can result in the exposure of the previously 'afterload-naive' (and therefore not adapted) transplanted organ to acutely increased afterload.

Management:

The management of RV failure should naturally aim to identify and treat any underlying aetiology. Generic treatment goals include optimising rate, rhythm, perfusion, preload, augmenting myocardial contractility and minimising afterload (Figure 1). This requires a careful balance of cardiac filling combined with vasopressor and inotropic support. In rare cases, surgical management may be required in the form of mechanical circulatory support.

- *Optimise rate and rhythm*

In general, it is considered preferable to keep the RV beating faster and where possible in sinus rhythm (SR). A relatively high heart rate (it is not uncommon to pace the immediately post-transplanted heart at 110 bpm), prevents excessive RV distention and subsequent

1
2
3 distortion of the LV and minimises TR. Additionally in conditions of failure where stroke
4
5 volume may be limited, a higher heart rate promotes cardiac output. Clinicians should
6
7 always be aware however of the effects of tachycardia on the LV blood supply and on its
8
9 function.
10
11
12
13
14

15 In theory, preservation of SR offers significant haemodynamic benefits, improving
16
17 ventricular preload as well as improving atrial emptying and reducing atrial pressures. In
18
19 many patients, non-sinus rhythm is a chronic situation however; attempts to restore SR
20
21 through chemical or electrical cardioversion should therefore be reserved for circumstances
22
23 where acute or paroxysmal arrhythmias are causing or exacerbating a patient's condition.
24
25
26
27
28
29
30

- 31 • *Maintaining Perfusion*

32
33
34
35
36
37 The importance of maintaining systemic arterial pressure, and right coronary perfusion
38
39 pressure is often under-appreciated in RV dysfunction where systemic hypotension can be
40
41 detrimental to the failing RV. Vasoconstrictor agents, such as noradrenaline or vasopressin
42
43 (Table 1), are often required to maintain systemic pressure, indirectly resulting in improved
44
45 RV function and global tissue perfusion.
46
47
48
49
50

51 Intra-aortic balloon pump counter pulsation (IABP) is a commonly used circulatory assist
52
53 device improving coronary and systemic blood flow.²² Whilst these devices are generally
54
55 considered to provide left sided support; improvement of right coronary perfusion can aid
56
57 RV function. The IABP inflates and deflates in harmony with the cardiac cycle; as diastolic
58
59
60

1
2
3 aortic pressure is augmented, coronary perfusion pressure is increased, improving coronary
4
5 blood flow and increasing myocardial oxygen supply.
6
7
8
9

- 10 • *Optimise preload*

11
12
13
14
15
16 Optimising RV preload by ensuring adequate filling pressure is important in patients with RV
17
18 dysfunction; even a functionally impaired ventricle has an optimal level of filling. Given the
19
20 potential for deleterious effects of over-distention however, it is common practice to assess
21
22 fluid responsiveness in patients with RV dysfunction by using small volume fluid boluses (50-
23
24 100ml) whilst paying close attention to CVP. In patients with RV dilatation, any increase in
25
26 intravascular volume can worsen dilatation and further impair LV diastolic filling. In the
27
28 dilated RV, marked diuresis is often warranted to offload the ventricle and reduce right-
29
30 sided filling pressures.
31
32
33
34
35
36
37

38 Exaggerated, ventilation induced (i.e. in response to cyclically varying afterload) changes in
39
40 SV and CO are common in the failing RV and can easily be misinterpreted as signs of 'fluid
41
42 responsiveness', rendering monitors assessing SV or systolic pressure variation less useful in
43
44 this context. Often the only reliable method of assessing preload responsiveness is the
45
46 judicious administration of a fluid bolus and observing the net change in SV or CO using an
47
48 appropriate CO monitor.
49
50
51
52
53

- 54 • *Reduce afterload*

1
2
3 Minimising afterload is a key component of RV management, though many patients
4
5 presenting with RV failure have chronic lung or cardiac diseases and consequently PH that
6
7 cannot easily be reversed. Iatrogenic increases in PVR should be avoided by careful
8
9 avoidance of hypoxia, hypercapnia and acidosis. When ventilating patients with RV failure
10
11 airway pressures should be minimised and PEEP used judiciously; both atelectasis and
12
13 excessive PEEP will increase PVR (Figure 2). Again, these goals appear in conflict to those
14
15 employed in patients with ARDS, where permissive hypercapnia and higher levels of PEEP
16
17 are commonplace.
18
19
20
21
22
23
24

25 Intravenous (IV) or inhaled pulmonary vasodilators may be used to reduce afterload by
26
27 targeting pathways implicated in PH. IV pulmonary vasodilators (e.g. GTN, flolan,
28
29 inodilators) cause indiscriminate vasodilation of the pulmonary vascular bed, blunting
30
31 hypoxic pulmonary vasoconstriction, leading to a worsening of any ventilation-perfusion
32
33 mismatch (V/Q) and potentially causing hypoxia. Systemic vasodilation occurs in parallel
34
35 and can cause systemic hypotension.
36
37
38
39
40
41

42 Inhaled vasodilators, such as nitric oxide, reduce PVR only in areas of the lung that are well
43
44 ventilated and so improve the V/Q matching by increasing flow to these areas, improving
45
46 oxygenation and decreasing PVR. Nitric oxide has a fast-onset of action with a short half-life
47
48 and has been shown to improve RV systolic function, mixed venous oxygen saturations and
49
50 haemodynamics in patients with acute RV failure. Nitric oxide may be of benefit in the peri-
51
52 operative and early post-operative period in patients with PH during cardiac surgery. There
53
54 is evidence for a reduction in PAP and an improvement in hypoxia in other clinical scenarios
55
56 such as ARDS, PE, and COPD; however, the evidence for an improvement in overall outcome
57
58
59
60

1
2
3 is lacking. Disadvantages include expense, the need for toxicity monitoring, platelet
4
5 inhibition, prolonged bleeding time and the potential for rebound hypoxaemia and PH.
6
7
8 Weaning of nitric oxide can be challenging and slow weaning over hours to days may be
9
10 required to avoid vasoconstriction and rebound pulmonary hypertension or hypoxaemia.
11
12
13

14
15 Oral phosphodiesterase type-5 inhibitors, such as sildenafil, reduce PVR and improve RV
16
17 contractility but caution should be exercised because of their long terminal half-life (4-
18
19 18hours) and risk of systemic hypotension as a result of systemic vasodilatation. In practice,
20
21 these agents tend to be used in stable disease rather than in the acute phase.
22
23
24

- 25
26
27 • *Optimise contractility*
28

29
30 Inodilatory vasoactive drugs, such as dobutamine, a beta agonist, or milrinone a
31
32 phosphodiesterase-3 inhibitor, are a natural choice in RV dysfunction promoting increased
33
34 contractility with a simultaneous reduction in afterload (Table 1). Both agents cause a
35
36 reduction in SVR and can lead to profound systemic hypotension, especially with milrinone.
37
38
39 As such, systemic vasoconstrictors are often required in conjunction with ino-dilators to
40
41 counteract the side effects described.
42
43
44

45
46
47
48 Levosimendan, a calcium sensitizer, may improve coronary perfusion and contractility
49
50 without increasing myocardial demand; however, its role in RV failure needs further
51
52 exploration.
53

- 54
55
56
57 • *Mechanical Support*
58
59
60

1
2
3 In isolated RV failure refractory to medical therapy or RV failure in the context of an LV
4 support device several options exist for mechanical circulatory support of the RV. It is
5
6 important to consider mechanical support early in order to prevent irreversible end organ
7
8 damage.
9
10
11
12
13

14
15 Peripheral venoarterial extracorporeal membrane oxygenation (ECMO - in contrast to
16
17 venovenous ECMO) provides respiratory and biventricular support via cannulae in the right
18
19 atrium (inserted via a peripheral vein) and in the subclavian or femoral artery.
20
21
22
23

24
25 Surgically implanted VADs provide isolated RV support classically via cannulae in the RA or
26
27 RV and an outflow cannula in the pulmonary artery. In recent years, so called
28
29 'percutaneously inserted' VAD devices such as the Impella RP and TandemHeart RVAD
30
31 devices have become increasingly popular, providing isolated RV support without the need
32
33 for sternotomy by accessing the pulmonary circulation via a transvalvular systemic venous
34
35 approach.
36
37
38
39
40
41
42
43

44 **Conclusions**

45
46
47
48
49
50

51
52 RV dysfunction and failure can occur as a result of a wide variety of pathophysiology and is
53
54 becoming more frequent in the general anaesthetic and intensive care population. Initial
55
56 management should aim to identify potential underlying reversible causes, optimise preload
57
58 and reduce afterload. Close attention should be paid to rate, rhythm and perfusion.
59
60

1
2
3 Pharmacological management may include a combination of inotropes, vasopressors, and
4
5
6 pulmonary vasodilators.
7
8
9
10
11
12
13
14

15 References

- 16
- 17
- 18 1. Murphy E, Shelley B. The right ventricle - structural and functional importance for
19 anaesthesia and intensive care. . *BJA Education* 2018;18(8):239-45.
- 20 2. Harjola V-P, Mebazaa A, Celutkiene J, et al. Contemporary management of acute right
21 ventricular failure: a statement from the Heart Failure Association and the Working
22 Group on Pulmonary Circulation and Right Ventricular Function of the European
23 Society of Cardiology. *European Journal of Heart Failure* 2016;18(3):226-41. doi:
24 10.1002/ejhf.478
- 25 3. Vieillard-Baron A, Naeije R, Haddad F, et al. Diagnostic workup, etiologies and
26 management of acute right ventricle failure. *Intensive Care Medicine* 2018;44(6):774-
27 90. doi: 10.1007/s00134-018-5172-2
- 28 4. Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary
29 hypertension. *J Am Coll Cardiol* 2013;62(25 Suppl):D34-41. doi:
30 10.1016/j.jacc.2013.10.029
- 31 5. Thenappan T, Ormiston ML, Ryan JJ, et al. Pulmonary arterial hypertension: pathogenesis
32 and clinical management. *BMJ* 2018;360:j5492. [published Online First: 2018/03/14]
- 33 6. R C. Critical care management of pulmonary hypertension. In: DG K, ed. *BJA Education*,
34 2017:228-34.
- 35 7. Kjaergaard J, Akkan D, Iversen KK, et al. Right ventricular dysfunction as an independent
36 predictor of short- and long-term mortality in patients with heart failure. *European*
37 *Journal of Heart Failure* 2007;9(6-7):610-16. doi: 10.1016/j.ejheart.2007.03.001
- 38 8. Almagro P, Barreiro B, Ochoa de Echaguen A, et al. Risk factors for hospital readmission
39 in patients with chronic obstructive pulmonary disease. *Respiration* 2006;73(3):311-7.
40 doi: 10.1159/000088092 [published Online First: 2005/09/06]
- 41 9. Gao Y, Du X, Qin W, et al. Assessment of the right ventricular function in patients with
42 chronic obstructive pulmonary disease using MRI. *Acta Radiol* 2011;52(7):711-5. doi:
43 10.1258/ar.2011.100449
- 44 10. Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in
45 the International Cooperative Pulmonary Embolism Registry (ICOPER). *Lancet*
46 1999;353(9162):1386-9.
- 47 11. A P, R DS, D J. *Pulmonary Embolism and Right Heart Failure. The Failing Right Heart:*
48 Springer, Cham 2015:127-138.
- 49 12. Condliffe R, Kiely DG, Gibbs JS, et al. Improved outcomes in medically and surgically
50 treated chronic thromboembolic pulmonary hypertension. *Am J Respir Crit Care Med*
51 2008;177(10):1122-7. doi: 10.1164/rccm.200712-1841OC [published Online First:
52 2008/02/21]
- 53 13. Zochios V, Parhar K, Tunnicliffe W, et al. The Right Ventricle in ARDS. *Chest*
54 2017;152(1):181-93. doi: 10.1016/j.chest.2017.02.019
55
56
57
58
59
60

14. Vieillard-Baron A, Jardin F. Why protect the right ventricle in patients with acute respiratory distress syndrome? *Curr Opin Crit Care* 2003;9(1):15-21.
15. Paternot A, Repesse X, Vieillard-Baron A. Rationale and Description of Right Ventricle-Protective Ventilation in ARDS. *Respiratory Care* 2016;61(10):1391-96. doi: 10.4187/respcare.04943
16. Vieillard-Baron A, Charron C, Caille V, et al. Prone positioning unloads the right ventricle in severe ARDS. *Chest* 2007;132(5):1440-46. doi: 10.1378/chest.07-1013
17. Sokmen A, Sokmen G, Acar G, et al. The Impact of Isolated Obesity on Right Ventricular Function in Young Adults. *Arquivos Brasileiros De Cardiologia* 2013;101(2):160-67. doi: 10.5935/abc.20130142
18. Kasai T, Bradley TD. Obstructive Sleep Apnea and Heart Failure Pathophysiologic and Therapeutic Implications. *Journal of the American College of Cardiology* 2011;57(2):119-27. doi: 10.1016/j.jacc.2010.08.627
19. Haddad F, Doyle R, Murphy DJ, et al. Right ventricular function in cardiovascular disease, part II: pathophysiology, clinical importance, and management of right ventricular failure. *Circulation* 2008;117(13):1717-31. doi: 10.1161/CIRCULATIONAHA.107.653584
20. Davlouros PA, Niwa K, Webb G, et al. The right ventricle in congenital heart disease. *Heart* 2006;92:127-138. doi: 10.1136/hrt.2005.077438
21. Argiriou M, Kolokotron SM, Sakellaridis T, et al. Right heart failure post left ventricular assist device implantation. *J Thorac Dis* 2014;6 Suppl 1:S52-9. doi: 10.3978/j.issn.2072-1439.2013.10.26
22. Krishna M, Zacharowski K. Principles of intra-aortic balloon pump counterpulsation. *BJA Education: Oxford Academic*, 2009:24-28.

MCQs**Question1:**

A 64-year-old male is admitted to ICU with Type 1 respiratory failure. His chest xray findings are consistent with acute respiratory distress syndrome (ARDS). He has an endotracheal tube placed and is ventilated. His current ventilation settings are FiO₂ 0.9, TV 550ml, RR 18, PEEP 8cmH₂O. His observations include BP 74/47mmHg MAP 58, HR 108bpm, lactate 6, venous oxygen saturations 48%. The following statements are true:

- a) An increased pulmonary vascular resistance (PVR) occurs during mechanical ventilation because of alveolar distension and extra-alveolar capillary compression.
- b) A bedside transthoracic echocardiograph would be an appropriate investigation in this patient.
- c) A driving pressure of >18cm H₂O is considered a risk factor for acute cor pulmonale.
- d) Proning may be beneficial in this patient to increased afterload.
- e) 'RV protective' ventilation strategies include adjusting tidal volume and PEEP to achieve a plateau pressure of >27cm H₂O

Answers:

- a) True. Alveolar distention during mechanical ventilation leads to compression of extra-alveolar capillaries increasing pulmonary vascular resistance (PVR) and RV afterload. In patients with ARDS, these effects are magnified as airway pressures rise in combination with the pulmonary vasoconstrictive effects of hypoxia and hypercapnia.

- 1
2
3 b) True. This patient is demonstrating non-specific signs of RV dysfunction including evidence
4 of hypoperfusion. A bedside TTE may demonstrate evidence of RV dysfunction which occurs
5 in around 15% of patients with ARDS.
6
7
8
9
10 c) True. Risk factors for acute pulmonale include an $P_{aO_2}/F_{I_{O_2}}$ of $< 150\text{mmHg}$ (20 kPa), $P_{aCO_2} >$
11 48mmHg (6.3kPa) and a driving pressure of $> 18\text{cm H}_2\text{O}$.
12
13
14 d) False. Proning could be useful in this patient as it has been shown to *reduce* afterload and
15 improve alveolar recruitment.
16
17
18
19 e) False. Tidal volume and PEEP should aim to maintain a plateau pressure less than $27\text{cmH}_2\text{O}$,
20 a driving pressure $< 18\text{cmH}_2\text{O}$ and ideally a $P_{aCO_2} < 48\text{mmHg}$
21
22
23
24
25
26
27
28

29 Question 2:

30 Appropriate statements regarding pharmacological management of right ventricular failure
31 (RVF) include:
32

- 33 a) Milrinone leads to an increase in pulmonary vascular resistance as a result of its role as a
34 PDE3 inhibitor
35
36
37
38 b) Noradrenaline works on the α_1 and β_1 receptors leading to vasoconstriction and increased
39 myocardial oxygen delivery.
40
41
42
43 c) Sildenafil can be inhaled via a nebuliser, administered intravenously or orally.
44
45
46
47 d) Vasopressin causes pulmonary vasodilatation
48
49
50
51
52
53 e) Nitric oxide has a half-life of less than 5 seconds
54
55
56
57
58
59
60

Answers:

Question 2

- 1
2
3
4
5
6
7
8 a. False. Milrinone is an ino-dilator that works on the PDE3 receptor causing a decrease
9
10 in pulmonary and systemic vascular resistance.
11
12
13 b. True. Noradrenaline works on the α_1 , β_1 with effects including vasoconstriction,
14
15 increased systemic and pulmonary vascular resistance, and increased myocardial
16
17 oxygen delivery.
18
19
20 c. False. Sildenafil has an oral and IV preparation but no nebulised form. Other
21
22 pulmonary vasodilators such as prostacyclin may be given in the nebulised form.
23
24
25 d. True. Vasopressin causes pulmonary vasodilatation as a result of its stimulation of
26
27 endothelial nitric oxide.
28
29
30 e. True. Inhaled NO reacts with oxidised haemoglobin to produce methaemoglobin
31
32 with a half-life of less than 5 seconds.
33
34
35
36
37
38
39
40
41
42
43
44

Question 3:

45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Regarding clinical conditions associated with right ventricular dysfunction:

- a. Right ventricular myocardial infarction occurs traditionally because of occlusion
of the left anterior descending artery.
- b. Atrial septal defects (ASD) can lead to volume overloaded RV failure.
- c. Repair of the tricuspid valve during cardiac surgery may lead to an increase in
preload.
- d. Pre-existing pulmonary hypertension is a risk factor for developing post-
operative RV dysfunction in cardiac transplant patients.

- 1
2
3 e. Following left ventricular assisted device insertion, the RV has to work harder as
4
5 a result of an increase in contractility.
6
7
8
9

10 Answers 3:

- 11
12
13 a. False. RVMI classically occurs because of an occlusion of the right coronary artery.
14
15 b. True. ASD defects are associated with volume overloaded RV failure. Other causes
16 include VSDs, pulmonary regurgitation and tricuspid regurgitation.
17
18 c. False. Repair of the tricuspid valve leads to an effective increase in afterload which
19 may affect RV function.
20
21 d. True. The transplanted heart may be exposed to increased afterload from pre-
22 existing pulmonary hypertension resulting in RV failure.
23
24 e. False. In comparison to the low cardiac output state encountered pre-operatively,
25 following LVAD implantation, the RV has to work harder to match the increased LV
26 output which leads to an effective increase in preload.
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44

45 Question 4:

46
47
48
49 Regarding the aetiology of right ventricular failure, the following statements are true:

- 50
51
52
53
54 a. During cardiac surgery, RV dysfunction may occur because of air embolism.
55
56 b. Negative intra-thoracic pressure, encountered in OSA, increases venous return and
57 consequently RV preload.
58
59
60

- 1
2
3 c. Patients with large VSD defects will present with pressure-overloaded RV failure.
4
5 d. RV failure may be encountered following LVAD insertion as a result of an increased preload.
6
7
8 e. LV failure is classified as WHO Class 1 Pulmonary Hypertension.
9
10
11
12

13 **Answers:**
14

- 15 a. True. The RV is particularly susceptible to post-operative dysfunction because of air
16 embolization. The RV is particularly predisposed because of the anterior location of the right
17 coronary ostia.
18
19
20
21
22 b. True. The negative intra-thoracic pressure, occurring during inspiration against an occluded
23 pharynx, increases venous return, and RV preload.
24
25
26
27 c. False. Ventricular septal defects (A- and V-SD) with left to right shunt and tricuspid and
28 pulmonary regurgitation may lead to volume-overloaded RV failure.
29
30
31
32 d. True. Following LVAD implantation, the RV is challenged by the need to match the increased
33 LV output which leads to an effective increase in preload and therefore potential RV failure.
34
35
36
37 e. False. LV failure is classified as post-capillary PH (WHO class II PH) and is associated with a
38 high pulmonary capillary wedge pressure
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Figure 1: Management of Right Ventricular Failure Algorithm.**
4

5 NO: nitric oxide. PH: pulmonary hypertension. DCCV: direct current cardioversion. CVP:
6 central venous pressure. CVVH: continuous venous-venous hemofiltration. IABP: intra-aortic
7 balloon pump. ECMO: extra-corporeal membrane oxygenation. VAD: ventricular assist device.
8
9
10
11
12
13 HR: Heart rate. SR: sinus rhythm. IV: Intravenous.
14
15
16
17

18 **Figure 2. Schematic representation of the relationship between lung volume and**
19 **pulmonary vascular resistance.**
20
21

22 The relationship of PVR and lung volumes. Atelectasis compresses extra-alveolar bloods
23 vessels which increases PVR. Alveolar distention, occurring at high lung volumes,
24
25 compresses intra-alveolar blood vessels which increases PVR.
26
27
28

29
30 RV - Residual volume (RV). Functional Residual Capacity (FRC). Total Lung Capacity (TLC).
31
32
33
34

35 **Table 1. Commonly used pharmacological agents in RV failure.**
36

37 IV: intravenous. Neb: Nebulised. SVR: systemic vascular resistance. PVR: pulmonary vascular
38 resistance. PH: Pulmonary hypertension. ^a A loading dose of milrinone may be given.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review

MCQs**Question1:**

A 64-year-old male is admitted to ICU with Type 1 respiratory failure. His chest x-ray findings are consistent with acute respiratory distress syndrome (ARDS). He has an endotracheal tube placed and is ventilated. His current ventilation settings are FiO₂ 0.9, TV 550ml, RR 18, PEEP 8cmH₂O. His observations include BP 74/47mmHg MAP 58, HR 108bpm, lactate 6, venous oxygen saturations 48%. The following statements are true:

- a) An increased pulmonary vascular resistance (PVR) occurs during mechanical ventilation due to alveolar distension and extra-alveolar capillary compression.
- b) A bedside transthoracic echocardiograph would be an appropriate investigation in this patient.
- c) A driving pressure of >18cm H₂O is considered a risk factor for acute cor pulmonale.
- d) Proning may be beneficial in this patient to increased afterload.
- e) 'RV protective' ventilation strategies include adjusting tidal volume and PEEP to achieve a plateau pressure of >27cm H₂O

Answers:

- a) True. Alveolar distention during mechanical ventilation leads to compression of extra-alveolar capillaries increasing pulmonary vascular resistance (PVR) and RV afterload. In patients with ARDS, these effects are magnified as airway pressures rise in combination with the pulmonary vasoconstrictive effects of hypoxia and hypercapnia.

- 1
2
3 b) True. This patient is demonstrating non-specific signs of RV dysfunction including evidence
4 of hypoperfusion. A bedside TTE may demonstrate evidence of RV dysfunction which occurs
5 in around 15% of patients with ARDS.
6
7
8
9
10 c) True. Risk factors for acute pulmonale include an $P_{aO_2}/F_{I_{O_2}}$ of $< 150\text{mmHg}$ (20 kPa), $P_{aCO_2} >$
11 48mmHg (6.3kPa) and a driving pressure of $> 18\text{cm H}_2\text{O}$.
12
13
14 d) False. Proning could be useful in this patient as it has been shown to *reduce* afterload and
15 improve alveolar recruitment.
16
17
18
19 e) False. Tidal volume and PEEP should aim to maintain a plateau pressure less than $27\text{cmH}_2\text{O}$,
20 a driving pressure $< 18\text{cmH}_2\text{O}$ and ideally a $\text{PaCO}_2 < 48\text{mmHg}$
21
22
23
24
25
26
27
28

29 Question 2:

30 Appropriate statements regarding pharmacological management of right ventricular failure
31 (RVF) include:
32

- 33 a) Milrinone leads to an increase in pulmonary vascular resistance due to its role as a PDE3
34 inhibitor
35
36
37
38 b) Noradrenaline works on the α_1 and β_1 receptors leading to vasoconstriction and increased
39 myocardial oxygen delivery.
40
41
42
43 c) Sildenafil can be inhaled via a nebuliser, administered intravenously or orally.
44
45
46
47 d) Vasopressin causes pulmonary vasodilatation
48
49
50
51
52
53
54
55
56
57
58
59
60

Answers:

Question 2

- 1
2
3
4
5
6 a. False. Milrinone is an ino-dilator that works on the PDE3 receptor causing a decrease
7
8 in pulmonary and systemic vascular resistance.
9
10
11 b. True. Noradrenaline works on the α_1 , β_1 with effects including vasoconstriction,
12
13 increased systemic and pulmonary vascular resistance, and increased myocardial
14
15 oxygen delivery.
16
17
18 c. False. Sildenafil has an oral and IV preparation but no nebulised form. Other
19
20 pulmonary vasodilators such as prostacyclin may be given in the nebulised form.
21
22
23 d. True. Vasopressin causes pulmonary vasodilatation due to its stimulation of
24
25 endothelial nitric oxide.
26
27
28 e. True. Inhaled NO reacts with oxidised haemoglobin to produce methaemoglobin
29
30 with a half-life of less than 5 seconds.
31
32
33
34

35 Question 3:
36
37
38
39

40 Regarding clinical conditions associated with right ventricular dysfunction:
41

- 42 a. Right ventricular myocardial infarction occurs traditionally due to occlusion of
43
44 the left anterior descending artery.
45
46
47 b. Atrial septal defects (ASD) can lead to volume overloaded RV failure.
48
49
50 c. Repair of the tricuspid valve during cardiac surgery may lead to an increase in
51
52 preload.
53
54
55 d. Pre-existing pulmonary hypertension is a risk factor for developing post-
56
57 operative RV dysfunction in cardiac transplant patients.
58
59
60

- 1
2
3 e. Following left ventricular assisted device insertion, the RV has to work harder
4
5 due to an increase in contractility.
6
7
8
9

10
11 Answers 3:

- 12
13 a. False. RVMI classically occurs due to occlusion of the right coronary artery.
14
15 b. True. ASD defects are associated with volume overloaded RV failure. Other causes
16 include VSDs, pulmonary regurgitation and tricuspid regurgitation.
17
18 c. False. Repair of the tricuspid valve leads to an effective increase in afterload which
19 may affect RV function.
20
21 d. True. The transplanted heart may be exposed to increased afterload from pre-
22 existing pulmonary hypertension resulting in RV failure.
23
24 e. False. In comparison to the low cardiac output state encountered pre-operatively,
25 following LVAD implantation, the RV has to work harder to match the increased LV
26 output which leads to an effective increase in preload.
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44

45 Question 4:

46
47
48
49 Regarding the aetiology of right ventricular failure, the following statements are true:

- 50
51
52
53
54 a. During cardiac surgery, RV dysfunction may occur due to air embolism.
55
56 b. Negative intra-thoracic pressure, encountered in OSA, increases venous return and
57 consequently RV preload.
58
59
60

- 1
2
3 c. Patients with large VSD defects will present with pressure-overloaded RV failure.
4
5 d. RV failure may be encountered following LVAD insertion due to an increased preload.
6
7
8 e. LV failure is classified as WHO Class 1 Pulmonary Hypertension.
9
10
11
12

13 **Answers:**
14

- 15 a. True. The RV is particularly susceptible to post-operative dysfunction due to air
16 embolization. The RV is particularly predisposed due to the anterior location of the right
17 coronary ostia.
18
19
20
21
22 b. True. The negative intra-thoracic pressure, occurring during inspiration against an occluded
23 pharynx, increases venous return, and RV preload.
24
25
26
27 c. False. Ventricular septal defects (A- and V-SD) with left to right shunt and tricuspid and
28 pulmonary regurgitation may lead to volume-overloaded RV failure.
29
30
31
32 d. True. Following LVAD implantation, the RV is challenged by the need to match the increased
33 LV output which leads to an effective increase in preload and therefore potential RV failure.
34
35
36
37 e. False. LV failure is classified as post-capillary PH (WHO class II PH) and is associated with a
38 high pulmonary capillary wedge pressure.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review

Drug	Classification	Dose	Receptor	Effects	Onset	Advantages	Disadvantages
Noradrenaline	Vasopressor	IV:0.02 – 0.2mcg/kg/min	α_1, β_1	Vasoconstriction ↑SVR, ↑Myocardial O ₂ delivery ↑PVR	Quick (mins)	Cheap Easy to titrate Familiarity	Arrhythmias ↑ PVR in higher doses
Vasopressin	Vasopressor	IV.: 1-4 units/min	V1, V2	Vasoconstriction, ↑SVR, Pulmonary vasodilatation at low doses via endothelial nitric oxide pathway ↑myocardial O ₂ delivery	Quick (mins)	Catecholamine sparing Less ↑ PVR than Noradrenaline Easy to titrate	Expensive Bradycardia Splanchnic ischaemia
Dobutamine	Inodilator	IV: 2.5-10mcg/kg/min	β_1, β_2	Inotropy ↑contractility ↓SVR, PVR	Quick (mins)	Easy to titrate Cheap	↑ O ₂ demand Tachy-arrhythmias Systemic hypotension
Milrinone	Inodilator	IV 0.375–0.75 mcg/kg/min ^a	PDE3 inhibitor	Inotropy ↑Contractility ↓SVR, PVR	Long half-life (2.5h)	Pulmonary vasodilatation	Systemic hypotension Expensive
Levosimendan	Inodilator	IV loading: 6–12 mcg/kg/min over 10 min followed by 0.1	Calcium sensitizer	↑Contractility	Slow	No effect on myocardial oxygen demand	Expensive Tachycardia Hypotension Headache


		mcg/kg/min					
Sildenafil	Pulmonary vasodilator	IV: 10mg TDS Oral: 20–100 mg TDS	PDE5 inhibitor	↓PVR ↑Contractility	Slow	Oral admin for patients with chronic disease.	Long terminal half-life (4-18h), ↓SVR
Epoprostenol	Pulmonary vasodilator	IV:1-2ng/kg/min Neb: 0.2–0.3 ml/min of 10–20 µg/ml	Prostacyclin	↓PVR ↑V/Q mismatch	Quick	As efficient as nitric oxide	Systemic hypotension with IV admin Flushing Headaches

Table 1. Commonly used pharmacological agents in RV failure.

IV: intravenous. Neb: Nebulised. SVR: systemic vascular resistance. PVR: pulmonary vascular resistance. PH: Pulmonary hypertension. ^a A loading dose of milrinone may be given but increases risk of systemic hypotension.

Management of Acute Right Ventricular Failure

In all cases identify and treat underlying aetiologies where possible






Figure 2. Schematic representation of the relationship between lung volume and pulmonary vascular resistance.

The relationship of PVR and lung volumes. Atelectasis compresses extra-alveolar blood vessels which increases PVR. Alveolar distention, occurring at high lung volumes, compresses intra-alveolar blood vessels which increases PVR.

RV - Residual volume (RV). Functional Residual Capacity (FRC). Total Lung Capacity (TLC).

176x196mm (72 x 72 DPI)